Estrella Immunopharma initiated with a Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert initiated coverage of Estrella Immunopharma (ESLA) with a Buy rating and $16 price target The firm says Estrella is poised to become a “significant player” in immuno-oncology. The company’s EB103 utilizes ARTEMIS T-cell engineering technology, a “Mark and Kill” approach that combines specially designed oncolytic viruses that label solid tumor cells, the analyst tells investors in a research note. D. Broal says this approach represents a potential breakthrough for next-generation T-cell therapies and opens up solid tumors.